Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
Status:
Withdrawn
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This research is studying two experimental drugs, abemaciclib and atezolizumab, alone and in
combination with each other, to learn about the safety and effectiveness of these treatments
and their side effects. This is an investigational study treatment for adult men with
metastatic castrate resistant prostate cancer (mCRPC) who have progressive disease despite
previous treatment with androgen deprivation therapy (ADT). One group of men (men without a
genetic mutation called "CDK12 loss") will receive abemaciclib therapy alone. Two other
groups of men (men with CDK12 loss in one group and men without CDK12 loss in the other) will
receive the combination of abemaciclib and atezolizumab. Another group of men with CDK12 loss
will receive atezolizumab therapy alone.